Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Genitourinary Cancers
Is there any upper limit of volume or shape of a prostate gland which would be a red flag to cytoreduce prior to treatment?
What is the upper limit of size you would consider offering a patient a five fraction regimen?
Answer from: Radiation Oncologist at Community Practice
Astro/aua consensus guidelines based on published data limits to 100cc or less
Comments
Radiation Oncologist at Varian Medical Systems/Allegheny health network
This consensus statement is for SBRT
860
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
No.
Sign in or Register to read more
4362
4375
Related Questions
Should rectal spacing only be considered routinely for patients who are at elevated risk of rectal toxicity?
How do you dose or sequence therapy to overcome radioresistance from oligometastatic disease from RCC?
What is the optimal duration of ADT for unfavorable intermediate risk or high risk localized prostate cancer treated with SBRT instead of conventionally fractionated or hypofractionated RT?
Does the presence of ductal adenocarcinoma change how you risk stratify or treat patients with localized prostate cancer?
Is there any way to safely to treat patients with mCRPC with 177-Lu PSMA who are on hemodialysis?
What are best practices for oncologists during the national platinum shortage?
For patients undergoing bladder preservation therapy with TMT, how do you manage the urinary urgency and frequency during and after treatment?
For patients with unfavorable intermediate risk prostate cancer, do you use decipher, or other genetic testing to determine whether you will include pelvic lymph nodes when you give definitive EBRT? Can you comment on using decipher to determine whether to give ADT and the length of ADT.
Does the presence of Atypical Intraductal Proliferation (AIP) on prostate needle biopsy influence your risk stratification?
Would you add ADT to EBRT for favorable intermediate risk patients with T1c prostate cancer by DRE and bilateral prostatic lobe involvement by MRI?
This consensus statement is for SBRT